Bcor deficiency perturbs erythro-megakaryopoiesis and cooperates with Dnmt3a loss in acute erythroid leukemia onset in mice.
Anemia, Macrocytic
/ genetics
Animals
Bone Marrow
/ pathology
Cell Cycle
/ genetics
DNA (Cytosine-5-)-Methyltransferases
/ genetics
DNA Methyltransferase 3A
Disease Models, Animal
Erythroid Cells
/ pathology
Leukemia, Erythroblastic, Acute
/ genetics
Mice
Mice, Knockout
Repressor Proteins
/ deficiency
Transcriptome
/ genetics
Journal
Leukemia
ISSN: 1476-5551
Titre abrégé: Leukemia
Pays: England
ID NLM: 8704895
Informations de publication
Date de publication:
07 2021
07 2021
Historique:
received:
16
06
2020
accepted:
20
10
2020
revised:
19
08
2020
pubmed:
8
11
2020
medline:
17
8
2021
entrez:
7
11
2020
Statut:
ppublish
Résumé
Recurrent loss-of-function mutations of BCL6 co-repressor (BCOR) gene are found in about 4% of AML patients with normal karyotype and are associated with DNMT3a mutations and poor prognosis. Therefore, new anti-leukemia treatments and mouse models are needed for this combinatorial AML genotype. For this purpose, we first generated a Bcor
Identifiants
pubmed: 33159179
doi: 10.1038/s41375-020-01075-3
pii: 10.1038/s41375-020-01075-3
pmc: PMC8257496
doi:
Substances chimiques
Bcor protein, mouse
0
Dnmt3a protein, mouse
0
Repressor Proteins
0
DNA (Cytosine-5-)-Methyltransferases
EC 2.1.1.37
DNA Methyltransferase 3A
EC 2.1.1.37
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1949-1963Subventions
Organisme : NIDDK NIH HHS
ID : R56 DK092883
Pays : United States
Organisme : NIA NIH HHS
ID : P01 AG036695
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA125123
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA183252
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK092883
Pays : United States
Organisme : Howard Hughes Medical Institute
Pays : United States
Références
Huynh KD, Fischle W, Verdin E, Bardwell VJ. BCoR, a novel corepressor involved in BCL-6 repression. Genes Dev. 2000;14:1810–23.
pubmed: 10898795
pmcid: 316791
Basso K, Dalla-Favera R. Roles of BCL6 in normal and transformed germinal center B cells. Immunological Rev. 2012;247:172–83.
Surapornsawasd T, Ogawa T, Moriyama K. Identification of nuclear localization signals within the human BCOR protein. Febs Lett. 2015;589:3313–20.
pubmed: 26054978
Isshiki Y, Iwama A. Emerging role of noncanonical polycomb repressive complexes in normal and malignant hematopoiesis. Exp Hematol. 2018;68:10–14.
pubmed: 30554637
Vidal M, Starowicz K. Polycomb complexes PRC1. and their function in hematopoiesis. Exp Hematol. 2017;48:12–31.
pubmed: 28087428
Yoshizato T, Dumitriu B, Hosokawa K, Makishima H, Yohida K, Townsley D, et al. Somatic mutations and clonal hematopoiesis in aplastic anemia. N Engl J Med. 2015;373:35–47.
pubmed: 26132940
pmcid: 7478337
Tiacci E, Grossmann V, Martelli MP, Kohlmann A, Haferlach T, Falini B. The corepressors BCOR and BCORL1: two novel players in acute myeloid leukemia. Haematologica. 2012;97:3–5.
pubmed: 22210327
pmcid: 3248923
Astolfi A, Fiore M, Melchionda F, Indio V, Bertuccio SN, Pession A. BCOR involvement in cancer. Epigenomics. 2019;11:835–55.
pubmed: 31150281
pmcid: 6595546
Grossmann V, Tiacci E, Holmes AB, Kohlmann A, Martelli MP, Kern W, et al. Whole-exome sequencing identifies somatic mutations of BCOR in acute myeloid leukemia with normal karyotype. Blood. 2011;118:6153–63.
pubmed: 22012066
Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik V, Paschka P, Roberts N, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374:2209–21.
pubmed: 27276561
pmcid: 4979995
Terada K, Yamaguchi H, Ueki T, Usuki K, Kobayashi Y, Tajika K, et al. Usefulness of BCOR gene mutation as a prognostic factor in acute myeloid leukemia with intermediate cytogenetic prognosis. Genes Chromosomes Cancer. 2018;57:401–8.
pubmed: 29663558
Shiba N, Yoshida K, Shiraishi Y, Okuno Y, Yamato G, Hara Y, et al. Whole-exome sequencing reveals the spectrum of gene mutations and the clonal evolution patterns in paediatric acute myeloid leukaemia. Br J Haematol. 2016;175:476–89.
pubmed: 27470916
de Rooij JDE, van den Heuvel-Eibrink MM, Hermkens MCH, Verboon LJ, Arentsen-Peters S, Fornerod M, et al. BCOR and BCORL1 mutations in pediatric acute myeloid leukemia. Haematologica. 2015;100:e194–5.
pubmed: 25596268
pmcid: 4420230
Herold T, Metzeler KH, Vosberg S, Hartmann L, Rollig C, Stolzel F, et al. Isolated trisomy 13 defines a homogeneous AML subgroup with high frequency of mutations in spliceosome genes and poor prognosis. Blood. 2014;124:1304–11.
pubmed: 24923295
Li M, Collins R, Jiao YC, Ouillette P, Bixby D, Erba H, et al. Somatic mutations in the transcriptional corepressor gene BCORL1 in adult acute myelogenous leukemia. Blood. 2011;118:5914–7.
pubmed: 21989985
pmcid: 3228503
Ng D, Thakker N, Corcoran CM, Donnai D, Perveen R, Schneider A, et al. Oculofaciocardiodental and Lenz microphthalmia syndromes result from distinct classes of mutations in BCOR. Nat Genet. 2004;36:411–6.
pubmed: 15004558
Kelly MJ, So J, Rogers AJ, Gregory G, Li J, Zethoven M, et al. Bcor loss perturbs myeloid differentiation and promotes leukaemogenesis. Nat Commun. 2019;10:1347.
pubmed: 30902969
pmcid: 6430802
Cao Q, Gearhart MD, Gery S, Shojaee S, Yang H, Sun H, et al. BCOR regulates myeloid cell proliferation and differentiation. Leukemia. 2016;30:1155–65.
pubmed: 26847029
pmcid: 5131645
Tara S, Isshiki Y, Nakajima-Takagi Y, Oshima M, Aoyama K, Tanaka T, et al. Bcor insufficiency promotes initiation and progression of myelodysplastic syndrome. Blood. 2018;132:2470–83.
pubmed: 30228234
pmcid: 6450057
Ley TJ, Ding L, Walter MJ, McLellan M, Lamprecht T, Larson D, et al. DNMT3A mutations in acute myeloid leukemia. N Engl J Med. 2010;363:2424–33.
pubmed: 21067377
pmcid: 3201818
Brunetti L, Gundry MC, Goodell MA. DNMT3A in Leukemia. Cold Spring Harb Perspect Med. 2017;7:a030320.
pubmed: 28003281
pmcid: 5287058
Ketkar S, Verdoni AM, Smith AM, Bangert CV, Leight ER, Chen DY, et al. Remethylation of Dnmt3a (-/-) hematopoietic cells is associated with partial correction of gene dysregulation and reduced myeloid skewing. Proc Natl Acad Sci USA. 2020;117:3123–34.
pubmed: 31996479
pmcid: 7022185
Challen GA, Sun DQ, Jeong M, Luo M, Jelinek J, Berg JS, et al. Dnmt3a is essential for hematopoietic stem cell differentiation. Nat Genet. 2012;44:23–43.
Mayle A, Yang L, Rodriguez B, Zhou T, Chang E, Curry CV, et al. Dnmt3a loss predisposes murine hematopoietic stem cells to malignant transformation. Blood. 2015;125:629–38.
pubmed: 25416277
pmcid: 4304108
Sportoletti P, Varasano E, Rossi R, Mupo A, Tiacci E, Vassiliou G, et al. Mouse model of NPM1-mutated acute myeloid leukemia: biological and clinincal implications. Leukemia. 2015;29:269–78.
pubmed: 25179729
Guryanova OA, Lieu YK, Garrett-Bakelman FE, Spitzer B, Glass JL, Shank K, et al. Dnmt3a regulates myeloproliferation and liver-specific expansion of hematopoietic stem and progenitor cells. Leukemia. 2016;30:1133–42.
pubmed: 26710888
Guryanova OA, Shank K, Spitzer B, Luciani L, Koche RP, Garrett-Bakelman FE, et al. DNMT3A mutations promote anthracycline resistance in acute myeloid leukemia via impaired nucleosome remodeling. Nat Med. 2016;22:1488–95.
pubmed: 27841873
pmcid: 5359771
Wang SM, Zhao YJ, Aguilar A, Bernard D, Yang CY. Targeting the MDM2-p53 protein-protein interaction for new cancer therapy: progress and challenges. Cold Spring Harb Perspect Med. 2017;7:a026245.
pubmed: 28270530
pmcid: 5411684
Iacobucci I, Wen J, Meggendorfer M, Choi JK, Shi L, Pounds SB, et al. Genomic subtyping and therapeutic targeting of acute erythroleukemia. Nat Genet. 2019;51:694–704.
pubmed: 30926971
pmcid: 6828160
Cole CB, Russler-Germain DA, Ketkar S, Verdoni AM, Smith AM, Bangert CV, et al. Haploinsufficiency for DNA methyltransferase 3A predisposes hematopoietic cells to myeloid malignancies. J Clin Invest. 2017;127:3657–74.
pubmed: 28872462
pmcid: 5617681
Zaidi U, Shahid S, Fatima N, Ahmed S, Sufaida G, Nadeem M, et al. Genomic profile of a patient with triple negative essential thrombocythemia, unresponsive to therapy: a case report and literature review. J Adv Res. 2017;8:375–8.
pubmed: 28560052
pmcid: 5435578
Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitiz M, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia (vol 127, pg 2391, 2016). Blood. 2016;128:462–3.
Damm F, Chesnais V, Nagata Y, Yoshida K, Scouriz L, Okuno Y, et al. BCOR and BCORL1 mutations in myelodysplastic syndromes and related disorders. Blood. 2013;122:3169–77.
pubmed: 24047651
McClure RF, Ewalt MD, Crow J, Temple-Smolkin R, Pullambhatla M, Sargent R, et al. Clinical significance of DNA variants in chronic myeloid neoplasms a report of the association for molecular pathology. J Mol Diagnostics. 2018;20:717–37.
Patnaik MM, Tefferi A. Refractory anemia with ring sideroblasts (RARS) and RARS with thrombocytosis: “2019 update on diagnosis, risk-stratification, and management”. Am J Hematol. 2019;94:475–88.
pubmed: 30618061
pmcid: 6408294
Li P, Shahmarvand N, Lynch D, Gotlib JR, Merker JD, Zehnder J, et al. Revisiting diagnostic criteria for myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis: borderline cases without anemia exist. Int J Lab Hematol. 2019;41:345–52.
pubmed: 30811101
Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitiz M, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391–405.
pubmed: 27069254
Arber DA. Revisiting erythroleukemia. Curr Opin Hematol. 2017;24:146–51.
pubmed: 27875373
Pellagatti A, Armstrong RN, Steeples V, Sharma E, Repapi E, Singh S, et al. Impact of spliceosome mutations on RNA splicing in myelodysplasia: dysregulated genes/pathways and clinical associations. Blood. 2018;132:1225–40.
pubmed: 29930011
pmcid: 6172604
Balduini CL. 100-Year old haematologica images: Di Guglielmo disease or pure erythroid leukemia. Haematologica. 2020;105:525.
pubmed: 32115409
pmcid: 7049379
Grossmann V, Bacher U, Haferlach C, Schnittger S, Potsinger F, Weissmann S, et al. Acute erythroid leukemia (AEL) can be separated into distinct prognostic subsets based on cytogenetic and molecular genetic characteristics. Leukemia. 2013;27:1940–3.
pubmed: 23648669
Cervera N, Carbuccia N, Garnier S, Guille A, Adelaide J, Murati A, et al. Molecular characterization of acute erythroid leukemia (M6-AML) using targeted next-generation sequencing. Leukemia. 2016;30:966–70.
pubmed: 26202927
Katsumura KR, Bresnick EH. The GATA factor revolution in hematology. Blood. 2017;129:2092–102.
pubmed: 28179282
pmcid: 5391619
Sportoletti P, Celani L, Varasano E, Rossi R, Sorcini D, Rompietti C, et al. GATA1 epigenetic deregulation contributes to the development of AML with NPM1 and FLT3-ITD cooperating mutations. Leukemia. 2019;33:1827–32.
pubmed: 30755706
pmcid: 6756200
Fagnan A, Otzen Bagger F, Piquè-Borras M, Ignacimouttou C, Caulier A, Lopez CK, et al. Human erythroleukemia genetics and transcriptomes identify master transcription factors as functional disease drivers. Blood. 2020. https://doi.org/10.1182/blood.2019003062 .
Montalban-Bravo G, Benton CB, Wang SA, Ravandi F, Kadia T, Cortes J, et al. More than 1 TP53 abnormality is a dominant characteristic of pure erythroid leukemia. Blood. 2017;129:2584–7.
pubmed: 28246192
pmcid: 5418636
Almeida AM, Prebet T, Itzykson R, Ramos F, Al-Ali H, Shammo J, et al. Clinical outcomes of 217 patients with acute erythroleukemia according to treatment type and line: A retrospective multinational study. Int J Mol Sci. 2017;18:837.
pmcid: 5412421
Welch JS, Petti AA, Miller CA, Fronick CC, O’Laughlin M, Fulton RS, et al. TP53 and decitabine in acute myeloid leukemia and myelodysplastic syndromes. N Engl J Med. 2016;375:2023–36.
pubmed: 27959731
pmcid: 5217532